Company profile: Taxis Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of anti-infective pharmaceuticals focused on discovery and development of novel agents, including TXA709, an oral anti-MRSA agent targeting the FtsZ bacterial cell division protein (completed Phase I), and efflux pump inhibitors for Gram-negative MDR pathogens by inhibiting resistance efflux pumps.
Products and services
- Efflux Pump Inhibition: TAXIS engineers a mechanism-based class of drugs that inhibit bacterial efflux pumps to combat Gram-negative MDR pathogens, directly suppressing pump-mediated antibiotic resistance
- Pharmaceutical Discovery and Development: TAXIS architects research-grade discovery and development programs for pharmaceuticals, reflecting its stated focus and advancing agents such as TXA709 and Efflux Pump Inhibitors
- TXA709 FtsZ Modulation: TAXIS produces a clinical-stage, oral anti-MRSA agent that targets the FtsZ bacterial cell division protein and has completed a Phase I clinical trial
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Taxis Pharmaceuticals
Coris BioConcept
HQ: Belgium
Website
- Description: Provider of rapid diagnostic kits, developing, marketing and selling assays including RESIST Range for antibiotic resistance (carbapenemase-producing organisms), Legionella K-SeT lateral flow test for Legionella pneumophila, HAT Sero K-SeT for Trypanosoma brucei gambiense, BL-RED electrochemical test for bacterial hydrolysis related to 3GC antibiotics, Giardia-Strip dipstick test, and RT-LAMP fluorescence assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coris BioConcept company profile →
LigoCyte Pharmaceuticals
HQ: United States
Website
- Description: Provider of vaccines and monoclonal antibodies for gastrointestinal and respiratory indications, developing novel immunomodulatory drug compounds that modify immune responses by targeting cell binding interactions for the treatment of inflammatory and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LigoCyte Pharmaceuticals company profile →
Romark
HQ: United States
Website
- Description: Provider of small-molecule therapies for infectious diseases and cancers, offering Alinia (nitazoxanide) for diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 1+; investigational NT-300 for COVID-19 and other viral respiratory illnesses; clinical trials and R&D in viral, cancer, pain, neurodegenerative and aging-related diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Romark company profile →
Vicebio
HQ: United Kingdom
Website
- Description: Provider of next-generation respiratory virus vaccines leveraging Molecular Clamp platform technology to stabilize viral glycoproteins in pre-fusion conformation, delivering broad protection and ready-to-use formulations. Pipeline includes bivalent RSV/hMPV (VXB-241), trivalent RSV-hMPV-PIV3, influenza A, SARS-CoV-2, and candidates for MERS, Ebola, and Nipah.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vicebio company profile →
Rempex Pharmaceuticals
HQ: United States
Website
- Description: Provider of new antibacterial drugs through discovery and development to meet clinical needs created by multi-drug resistant bacterial pathogens; San Diego-based, with an internal pipeline combining proprietary formulations and PK/PD strategies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rempex Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Taxis Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Taxis Pharmaceuticals
2.2 - Growth funds investing in similar companies to Taxis Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Taxis Pharmaceuticals
4.2 - Public trading comparable groups for Taxis Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →